Infliximab for the treatment of refractory polyarteritis nodosa

  • Shira GinsbergEmail author
  • Itzhak Rosner
  • Gleb Slobodin
  • Michael Rozenbaum
  • Lisa Kaly
  • Nizar Jiries
  • Nina Boulman
  • Abid Awisat
  • Haya Hussein
  • Irina Novofastovski
  • Amal Silawy
  • Doron Rimar
Case Based Review


Polyarteritis nodosa (PAN) is a necrotizing vasculitis predominantly affecting medium and small size arteries. Cyclophosphamide, a drug with narrow therapeutic range and poor safety profile, constitutes the treatment of choice for PAN vasculitis with major organ involvement. To describe our clinical experience in treating refractory PAN with infliximab (a TNF inhibitor), a drug with good tolerability and better safety profile than cyclophosphamide. Twenty-six PAN patients were admitted to our rheumatology unit between 2006 and 2017, of whom nine patients, with severe and refractory disease, were treated with infliximab after failure of standard treatment. We describe herein the patients’ characteristics, clinical manifestations, severity and response to infliximab treatment and review the current literature. Complete remission was defined as the absence of features of active disease and withdrawal of prednisone therapy. Significant improvement was defined as clinical improvement and prednisone dose reduction of at least 50% or a 50% reduction in immune modulatory medications other than prednisone. After 4 months of treatment, 8/9 (89%) patients achieved significant improvement, with two of them achieving complete remission. We suggest that anti-TNF agents, and in particular infliximab, are relatively safe and efficacious treatment options in refractory PAN. A randomized controlled trial should be done in order to objectively evaluate infliximab in PAN.


Infliximab Polyarteritis nodosa 


Compliance with ethical standards




  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11CrossRefGoogle Scholar
  2. 2.
    De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M, Martellucci S, de Vincentiis M (2016) Polyarteritis nodosa: a contemporary overview. Autoimmun Rev 15:564–570CrossRefGoogle Scholar
  3. 3.
    Lhote F, Cohen P, Guillevin L (1998) Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 7:238–258CrossRefGoogle Scholar
  4. 4.
    Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90:19–27CrossRefGoogle Scholar
  5. 5.
    Mahr A, Guillevin L, Poissonnet M, Aymé S (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51:92–99CrossRefGoogle Scholar
  6. 6.
    Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, Noël LH, Trépo C (1995) Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74:238–253CrossRefGoogle Scholar
  7. 7.
    Selga D, Mohammad A, Sturfelt G, Segelmark M (2006) Polyarteritis nodosa when applying the Chapel Hill nomenclature—a descriptive study on ten patients. Rheumatology (Oxford) 45:1276–1281CrossRefGoogle Scholar
  8. 8.
    Teles KA, Medeiros-Souza P, Lima FAC, Araújo BG, Lima RAC (2017) Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev Bras Reumatol Engl Ed 57:596–604CrossRefGoogle Scholar
  9. 9.
    Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A et al (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 38:1120–1127CrossRefGoogle Scholar
  10. 10.
    Matsuo S, Hayashi K, Morimoto E, Sada KE, Watanabe H, Takano-Narazaki M et al (2017) The successful treatment of refractory polyarteritis nodosa using infliximab. Intern Med 56:1435–1438CrossRefGoogle Scholar
  11. 11.
    Saunier A, Issa N, Vandenhende MA, Morlat P, Doutre MS, Bonnet F (2017) Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach? RMD Open 3(1):e000446CrossRefGoogle Scholar
  12. 12.
    Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, Kaly L, Boulman N, Awisat A, Ginsberg S, Zilber K, Shen-Orr SS (2016) Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis 75:2214–2216CrossRefGoogle Scholar
  13. 13.
    Sery Y, Shoda H, Hanata N, Nagafuch Y, Sumitomo S, Fujio K et al (2017) A case of refractory polyarteritis nodosa successfully treated with rituximab. Mod Rheumatol 27:696–698CrossRefGoogle Scholar
  14. 14.
    Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, Dolezalova P, Ozen S, Pilkington C, Woo P, Klein N, Dillon MJ, Brogan PA (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology 48:978–986CrossRefGoogle Scholar
  15. 15.
    Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093CrossRefGoogle Scholar
  16. 16.
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939CrossRefGoogle Scholar
  17. 17.
    Hernández-Rodríguez J, Alba MA, Prieto-González S, Cid MC (2014) Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48-49:84–89CrossRefGoogle Scholar
  18. 18.
    Vega Gutierrez J, Rodriguez Prieto MA, Garcia Ruiz JM (2007) Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 21:570–571Google Scholar
  19. 19.
    Capuozzo M, Ottaiano A, Nava E, Cascone S, Fico R, Laffaioli RV et al (2014) Etanercept induces remission of polyarteritis nodosa: a case report. Front Pharmacol 5:122CrossRefGoogle Scholar
  20. 20.
    Campanilho-Marques R, Ramos F, Canhão H, Fonseca JE (2014) Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab. Joint Bone Spine 81:267–268CrossRefGoogle Scholar
  21. 21.
    Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y et al (2016) ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open 16:2Google Scholar
  22. 22.
    Zoshima T, Matsumura M, Suzuki Y, Kakuchi Y, Mizushima I, Fujii H, Yamada K, Yamagishi M, Kawano M (2013) A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade. Mod Rheumatol 23:1029–1033CrossRefGoogle Scholar
  23. 23.
    Wu K, Throssell D (2006) A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 21:1710–1712CrossRefGoogle Scholar
  24. 24.
    Al-Bishri J, le Riche N, Pope JE (2005) Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 32:1371–1373Google Scholar
  25. 25.
    De Kort SW, van Rossum MA, ten Cate R (2006) Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol 25:769–771CrossRefGoogle Scholar
  26. 26.
    Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheum 68:2314–2322CrossRefGoogle Scholar
  27. 27.
    Wahezi DM, Gomes WA, Ilowite NT (2010) Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment. Pediatrics 126:e719–e722CrossRefGoogle Scholar
  28. 28.
    Rozin AP, Egozi D, Ramon Y, Toledano K, Braun-Moscovici Y, Markovits D et al (2011) Large leg ulcers due to autoimmune diseases. Med Sci Monit 17:1–7CrossRefGoogle Scholar
  29. 29.
    Navon Elkam P, Pierce SB, Segal R, Walsh T, Barash J, Padeh S (2014) Mutant adenosine deaminase 2 in polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931CrossRefGoogle Scholar
  30. 30.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304CrossRefGoogle Scholar
  31. 31.
    Jarrot PA, Kaplanski G (2014) Anti-TNF-alpha therapy and systemic Vasculitis. Mediat Inflamm 2014:1–9. CrossRefGoogle Scholar
  32. 32.
    Chang SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21:3–9CrossRefGoogle Scholar
  33. 33.
    Grau GE, Roux-Lombard P, Gysler C, Lambert C, Lambert PH, Dayer JM (1989) Serum cytokine in systemic vasculitis. Immunology 68:196–198Google Scholar
  34. 34.
    Deguchi Y, Shibata N, Kishimoto S (1990) Enhanced expression of the tumor necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 81:311–314CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Shira Ginsberg
    • 1
    • 2
    Email author
  • Itzhak Rosner
    • 1
  • Gleb Slobodin
    • 1
  • Michael Rozenbaum
    • 1
  • Lisa Kaly
    • 1
  • Nizar Jiries
    • 1
    • 2
  • Nina Boulman
    • 1
  • Abid Awisat
    • 1
  • Haya Hussein
    • 1
  • Irina Novofastovski
    • 3
  • Amal Silawy
    • 1
  • Doron Rimar
    • 1
  1. 1.Rheumatology UnitBnai-Zion Medical CenterHaifaIsrael
  2. 2.Internal Medicine B DepartmentBnai Zion Medical CenterHaifaIsrael
  3. 3.Rheumatic Diseases UnitHa’Emek Medical CenterAfulaIsrael

Personalised recommendations